Myriad Genetics

Myriad Genetics

Yahoo Finance • 17 hours ago

Myriad outlines $780M-$790M 2026 revenue outlook following $210M Prenatal Health divestiture deal

Earnings Call Insights: Myriad Genetics (MYGN) Q3 2026 MANAGEMENT VIEW * “We understand the key challenges that we've been facing, continued softness in our Prenatal Health business, reimbursement pressure on HCT and financial stabilit... Full story

Yahoo Finance • 17 days ago

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks rose late Tuesday afternoon with the NYSE Healthcare Index gaining 2.2% and the St PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 24 days ago

Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors

RAHWAY, N.J., October 13, 2026--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Paul J. Diaz, managing partner at Cressey & Company, will join the C... Full story

Yahoo Finance • 29 days ago

SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

BOSTON, Oct. 8, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support pr... Full story

Yahoo Finance • 29 days ago

Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology

Myriad Genetics, Inc. SALT LAKE CITY and BOSTON, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine and SOPHiA GENETICS (NASDAQ: SOPH) today announce a... Full story

Yahoo Finance • last month

1 Volatile Stock on Our Buy List and 2 We Question

1 Volatile Stock on Our Buy List and 2 We Question A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south. While some investors embrace risk, mistakes can be costly for those who aren't p... Full story

Yahoo Finance • last month

3 Reasons MYGN is Risky and 1 Stock to Buy Instead

3 Reasons MYGN is Risky and 1 Stock to Buy Instead Over the past six months, Myriad Genetics's stock price fell to $4.01. Shareholders have lost 13% of their capital, which is disappointing considering the S&P 500 has climbed by 18.4%. Th... Full story

Yahoo Finance • last month

Reflecting On Therapeutics Stocks’ Q2 Earnings: AbbVie (NYSE:ABBV)

Reflecting On Therapeutics Stocks' Q2 Earnings: AbbVie (NYSE:ABBV) Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look at AbbVie (NYSE:ABBV) and its peers. Over the... Full story

Yahoo Finance • 2 months ago

Quest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges

Key Points Interested in Quest Diagnostics Incorporated? Here are five stocks we like better. Quest Diagnostics is outperforming its growth targets: Revenue increased about 12% and earnings more than 10% in 2025, while 2026 guidance calls... Full story

Yahoo Finance • 2 months ago

1 Unpopular Stock That Deserves Some Love and 2 We Turn Down

1 Unpopular Stock That Deserves Some Love and 2 We Turn Down When Wall Street turns bearish on a stock, it's worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will l... Full story

Yahoo Finance • 2 months ago

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks As the Q2 earnings season wraps, let's dig into this quarter's best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:... Full story

Yahoo Finance • 2 months ago

Stocks making big moves yesterday: Myriad Genetics, Greenbrier, Tidewater, Strategy, and Charter

Stocks making big moves yesterday: Myriad Genetics, Greenbrier, Tidewater, Strategy, and Charter Check out the companies making headlines yesterday: Myriad Genetics (NASDAQ:MYGN): Genetic testing company Myriad Genetics (NASDAQ:MYGN) fel... Full story

Yahoo Finance • 2 months ago

Robinhood upgraded, Uber initiated: Wall Street's top analyst calls

Robinhood upgraded, Uber initiated: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled b... Full story

Yahoo Finance • 3 months ago

3 Healthcare Stocks with Open Questions

3 Healthcare Stocks with Open Questions Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only ri... Full story

Yahoo Finance • 3 months ago

MYRIAD INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Myriad Genetics, Inc. on Behalf of Myriad Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Myriad (MYGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Myriad and would like to discus... Full story

Yahoo Finance • 3 months ago

Endometrial Cancer Market Share Analysis and Industry Trends (2026-2031) Featuring Merck, Eisai, Karyopharm Therapeutics, Context Therapeutics, Seagen and More

Company Logo Opportunities center on frontline immunotherapy combinations, biomarker and companion diagnostics, AI-enabled pathology, minimally invasive screening, precision therapies for uterine sarcomas, and tele-oncology expansion in u... Full story

Yahoo Finance • 3 months ago

Myriad Genetics Q2 Loss Narrows; Revenue Falls 11%

(RTTNews) - Myriad Genetics, Inc. (MYGN) on Thursday reported a narrower loss for the second quarter despite a 11% decline in revenue, as last year's results were affected by a hefty goodwill impairment charge. The molecular diagnostics co... Full story

Yahoo Finance • 3 months ago

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Highlights Second quarter 2026 revenue of $190.7 million decreased 11% year-over-year, reflecting a 1% decline in volume and a 9% decrease in average revenue per test year-over-year. The company is engaging payers and executing revenue cy... Full story

Yahoo Finance • 4 months ago

Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1

Spotting Winners: Gilead Sciences (NASDAQ:GILD) And Therapeutics Stocks In Q1 Quarterly earnings results are a good time to check in on a company's progress, especially compared to its peers in the same sector. Today we are looking at Gil... Full story

Yahoo Finance • 4 months ago

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

SALT LAKE CITY, July 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces newly published data from the largest individual-patient-data meta-a... Full story